Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Therapies Need Cardiovascular Safety Data For Approval, Panel Says

Executive Summary

Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting
Advertisement

Related Content

Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
Don’t Forget Injectable Insulin, Novo Nordisk Says
FDA Looks To Outcomes Research In Move To Quantify Risk/Benefit Decisions
Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say
Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say
Cardiac Outcomes Studies For Diabetes Drugs Pose Trial Design Challenges
Avandia Concerns Highlight Need To Change Diabetes Approval Standards
Avandia Concerns Highlight Need To Change Diabetes Approval Standards
Advertisement
UsernamePublicRestriction

Register

PS049834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel